Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ultragenyx Pharmaceutical (RARE) Return on Assets (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Return on Assets for 10 consecutive years, with 0.42% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Assets fell 5.0% to 0.42% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.42%, a 5.0% decrease, with the full-year FY2025 number at 0.38%, changed 0.0% from a year prior.
  • Return on Assets was 0.42% for Q4 2025 at Ultragenyx Pharmaceutical, up from 0.47% in the prior quarter.
  • In the past five years, Return on Assets ranged from a high of 0.12% in Q1 2021 to a low of 0.53% in Q2 2023.
  • A 5-year average of 0.39% and a median of 0.4% in 2024 define the central range for Return on Assets.
  • Peak YoY movement for Return on Assets: rose 24bps in 2021, then decreased -22bps in 2022.
  • Ultragenyx Pharmaceutical's Return on Assets stood at 0.3% in 2021, then tumbled by -47bps to 0.45% in 2022, then grew by 1bps to 0.44% in 2023, then grew by 16bps to 0.37% in 2024, then dropped by -13bps to 0.42% in 2025.
  • Per Business Quant, the three most recent readings for RARE's Return on Assets are 0.42% (Q4 2025), 0.47% (Q3 2025), and 0.41% (Q2 2025).